Moberg Pharma AB (publ) (MOB) Q4 2024 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Moberg Pharma Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.655 Hello, everyone, and thank you for joining the Moberg Pharma Q4 Report call. 00:00:04.655 -- 00:00:07.298 My name is Marie, and I will be coordinating your call today. 00:00:07.298 -- 00:00:12.243 During the presentation, you can register your question by pressing star followed by 00:00:12.243 -- 00:00:16.747 one on your telephone keypad. If you change your mind, please press star followed by 00:00:16.747 -- 00:00:22.373 two. I will now hand over to your host, Anna Leong, CEO, to begin. 00:00:22.373 -- 00:00:23.133 Please go ahead. 00:00:23.133 -- 00:00:25.133 Thank 00:00:26.196 -- 00:00:31.135 you, and good afternoon, everyone. Thank you for joining our Q4 earnings call today. 00:00:31.135 -- 00:00:35.620 I'm Anna Jöns, CEO of Moberg Pharma, and I also have our VP of Finance, Mark Beveridge, 00:00:35.620 -- 00:00:41.307 with me here today. We're happy to present our Q4 report that you can find on our webpage. 00:00:41.307 -- 00:00:46.112 There you can also find a PowerPoint presentation that I both based this call upon. 00:00:46.112 -- 00:00:50.037 This call will be recorded and uploaded to our webpage. 00:00:50.037 -- 00:00:54.743 In today's call, I will provide an overview of our performance this quarter, key business 00:00:54.743 -- 00:01:00.807 developments, and highlights to take into initiatives shaping our path forward. 00:01:00.807 -- 00:01:05.972 I am proud to report that Perklara continues to lead the Swedish market, achieving 00:01:05.972 -- 00:01:11.437 31% market share in value and 25% in units for the full year 00:01:11.437 -- 00:01:16.722 in pharmacy sales and consumers, despite consumer marketing launching only in the beginning 00:01:16.722 -- 00:01:21.766 of April. Importantly, momentum continued in Q4, with figur...